ADC Therapeutics S.A.ADCTNYSE
LOADING
|||
Switch Symbol:
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-10.92%
↓ 1038% below average
Average (30q)
1.17%
Historical baseline
Range
High:50.99%
Low:-26.64%
Volatility
6664.0%
High variability
| Period | Value |
|---|---|
| Q3 2025 | -10.92% |
| Q2 2025 | 4.02% |
| Q1 2025 | 6.74% |
| Q4 2024 | -16.62% |
| Q3 2024 | 33.78% |
| Q2 2024 | -5.60% |
| Q1 2024 | -15.15% |
| Q4 2023 | 6.65% |
| Q3 2023 | -9.26% |
| Q2 2023 | -18.33% |
| Q1 2023 | -21.25% |
| Q4 2022 | 16.93% |
| Q3 2022 | -14.14% |
| Q2 2022 | -0.85% |
| Q1 2022 | 15.20% |
| Q4 2021 | 15.45% |
| Q3 2021 | -6.90% |
| Q2 2021 | 0.92% |
| Q1 2021 | -19.32% |
| Q4 2020 | 50.99% |
| Q3 2020 | 23.91% |
| Q2 2020 | -26.64% |
| Q1 2020 | 16.27% |
| Q4 2019 | -0.38% |
| Q3 2019 | 40.35% |
| Q2 2019 | -6.55% |
| Q1 2019 | -19.95% |
| Q4 2018 | 0.00% |
| Q3 2018 | -3.25% |
| Q2 2018 | 0.00% |
| Q1 2018 | 0.00% |